Mutant CALR-specific monoclonal antibodies
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-30 — Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms: cross-connection with dmr-001-mutant-calr-antibody: DMR-001 is a specific clinical-stage asset within the broader mutant CALR monoclonal antibody class, now entering first-in-human Phase 1/1b testing. (novelty: 4)
Open questions
Related
Contributing findings
Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms.
18-aug-2026
novelty 2
per-area 4
introduces